CD30+ LYMPHOMA
Clinical trials for CD30+ LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CD30+ LYMPHOMA trials appear
Sign up with your email to follow new studies for CD30+ LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New weekly combo offers hope for hard-to-treat lymphoma
Disease control OngoingThis study tests whether giving the drug brentuximab vedotin weekly, alone or with nivolumab, can shrink tumors in people with CD30+ lymphoma that no longer responds to the usual every-3-week dosing. About 28 adults with relapsed or refractory Hodgkin or non-Hodgkin lymphoma will…
Matched conditions: CD30+ LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
Engineered immune cells aim to stop lymphoma relapse after transplant
Disease control OngoingThis early-phase study tests a treatment that adds a special antibody to a patient's own immune cells (T cells) to help them find and attack lymphoma cells. The goal is to find a safe dose of these modified cells to give after a stem cell transplant, to try to prevent the cancer …
Matched conditions: CD30+ LYMPHOMA
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC